Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index; 13 of the 30 sources its claims cite were checked for support.
Abstract
New fecal microbiota for cancer patients: The composition of the gut microbiome influences the response of cancer patients to immunotherapies. Baruch et al. and Davar et al. report first-in-human clinical trials to test whether fecal microbiota transplantation (FMT) can affect how metastatic melanoma patients respond to anti–PD-1 immunotherapy (see the Perspective by Woelk and Snyder). Both studies observed evidence of clinical benefit in a subset of treated patients. This included increased abundance of taxa previously shown to be associated with response to anti–PD-1, increased CD8 + T cell activation, and decreased frequency of interleukin-8–expressing myeloid cells, which are involved in immunosuppression. These studies provide proof-of-concept evidence for the ability of FMT to affect immunotherapy response in cancer patients. Science , this issue p. 602 , p. 595 ; see also p. 573
Overview
CoChat Summary
TL;DR
In a single-arm trial, fecal microbiota transplantation (FMT) from anti–PD-1 responders plus pembrolizumab was well tolerated and produced clinical benefit in 6 of 15 evaluable patients with PD-1–refractory melanoma. Responders showed donor microbiome implantation, increased CD8+ T cell activation, and reduced IL-8–expressing myeloid cells.
Key findings
- Among 15 evaluable patients, objective responses occurred in 3 (20%: one complete response, two partial responses), and durable stable disease lasting >12 months occurred in another 3 (20%), for clinical benefit in 6 of 15. Median progression-free survival and overall survival were 3.0 and 7.0 months overall, and 14.0 and 14.0 months in the six patients with disease control.
- FMT caused durable gut microbiota perturbation; responders’ microbiota shifted toward donor composition, whereas nonresponders were heterogeneous. Responders also had greater donor bacteria–specific IgG responses and enrichment of taxa previously linked to anti–PD-1 response, including Firmicutes and Actinobacteria, with decreases in Bacteroidetes.
- Responders showed higher post-treatment CD56+CD8+ T cells, increased CD8+ T cell activation/differentiation markers, and more granzyme B–expressing MAIT cells. Tumor single-cell RNA sequencing showed fewer myeloid cells and regulatory T cells in responders, with lower myeloid CXCL8/IL-8 and SPP1 expression.
- Serum profiling showed responders had decreased circulating CCL2, CXCL8/IL-8, IL-18, IL-12p70, and IFN-γ, and increased IL-21, CXCL13, type II cytokines, and TNF-family cytokines. Metabolomic/lipidomic changes included more efficient primary-to-secondary bile acid conversion and altered triacylglycerol/monoacylglycerol/diacylglycerol levels. A transkingdom network of 371 nodes and 819 edges linked microbial taxa to host metabolomic and proteomic features.
Methods
- Single-arm clinical trial (NCT03341143) in patients with metastatic melanoma primary refractory to anti–PD-1. Sixteen patients were enrolled; 15 received colonoscopic FMT from seven anti–PD-1 responder donors plus pembrolizumab and were evaluable for response.
- Serial blood and stool sampling was performed, with infectious screening for 32 agents before FMT. Response was assessed by RECIST v1.1 every 12 weeks.
- Analyses included shotgun metagenomic sequencing of 223 fecal samples from recipients and donors, multiparameter flow cytometry of PBMCs, single-cell RNA sequencing of 64,340 CD45+ cells from 17 tumor samples, serum cytokine/chemokine profiling, metabolomics/lipidomics, and transkingdom network analysis.
Limitations
- The paper states that findings are preliminary and warrant evaluation in a larger randomized clinical trial; it also notes that insufficient tumor tissue was available to assess tumor mutation burden, PD-L1 expression, or IFN-γ gene expression signature as predictors of outcome.
- The text makes evident that the study is small and single-arm, limiting causal inference and comparison with standard-of-care outcomes; some analyses, such as the speed of microbiome change, did not reach statistical significance, which the authors attribute to limited sample size.
- The text also makes evident heterogeneity in nonresponders’ donor microbiota implantation and notes that nonresponse may reflect patient immunodeficiency, lack of tumor immunogenicity, absence of necessary taxa in the FMT, or failure of FMT implantation.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 0 Not valid · 5 Not checked · 45 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“the gut microbiome is a major tumor-extrinsic regulator of responses to anti–PD-1 (6–9).”
§ Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients > Abstract
What the sources say
- Partly supportedcites [6] Dzutsev A, Goldszmid RS, Viaud S, Zitvogel L, Trinchieri G, Eur. J. Immunol 45, 17– 31 (2015). 25328099 sourceExperimental — accuracy not yet measured
In 'The commensal microbiota controls the response to cancer therapy' our copy confirms that the gut microbiota modulates responses to cancer immunotherapy, chemotherapy, TBI and adoptive T-cell transfer (via myeloid-cell conditioning; see also Fig. 2 legend in Concluding remarks). But for checkpoint blockade the paper states only a hypothesis: after noting progress with anti-CTLA-4/anti-PD-1 antibodies [107], it says the data 'suggest the possibility that the microbiota may also modulate the clinical effectiveness of this new class of anticancer drugs.' The citing sentence therefore presents as an established, major regulator of anti-PD-1 responses what this source explicitly hedges as a suggested possibility, and no anti-PD-1 microbiome experiment is reported in our copy. (LLM, conf=0.78)
- Not checked yetcites [7] Finlay BB, Nat. Rev. Immunol 20, 522– 528 (2020). 32661409 source
- Partly supportedcites [8] Goldszmid RS, Cancer Immunol. Res 3, 103– 109 (2015). 25660553 PMC4324508 sourceExperimental — accuracy not yet measured
In 'Impact of commensal microbiota on cancer therapy' our copy states that 'The gut microbiota influences the response to cancer immunotherapy and chemotherapy by affecting the differentiation and functions of myeloid cells in the tumor microenvironment', and documents microbiota/antibiotic effects on CpG-ODN plus anti-IL10R, cyclophosphamide, oxaliplatin, TBI and adoptive CD8+ T-cell transfer — so the tumor-extrinsic, myeloid-priming part of the claim is supported. However, PD-1 appears only in 'Clinical perspectives' as one of the successful checkpoint approaches ('inhibition of immune checkpoints, such as CTLA-4 and PD-1/PD-L1/2'), with no linkage to microbiota; the paper instead only speculates that 'the variable response to cancer therapy observed in patients may be in part due to different microbiota composition'. Searches for 'anti-PD-1', checkpoint-blockade response and microbiota-control-of-checkpoint-efficacy returned no passage tying the microbiome to anti–PD-1 outcomes, so the specific anti–PD-1 qualifier of the claim is not supported by this source (it likely rests on the other references in the cluster 6–9). (LLM, conf=0.72)
- Could not verifycites [9] Zarour HM, Clin. Cancer Res 22, 1856– 1864 (2016). 27084739 PMC4872712 sourceExperimental — accuracy not yet measured
Our copy of Zarour (2016) is complete and discusses tumor-extrinsic drivers of anti-PD-1 response only in terms of the tumor microenvironment: soluble mediators (IL-10, IDO, VEGF-A, adenosine/A2aR, CSF-1R), suppressive cells (Tregs, TAM/MDSC), metabolic checkpoints (hypoxia/HIF-1α) and mutational/neoepitope burden correlating with clinical response (Therapeutic Strategies section). No passage mentions the gut microbiome, microbiota, or antibiotics; searches for 'gut microbiome/microbiota regulates response to anti-PD-1', 'microbiota composition antibiotic impact immunotherapy efficacy tumor-extrinsic', and 'bacterial composition fecal transplant' returned only TME-related and reference-list passages. The paper therefore neither supports nor contradicts the attributed claim. (LLM, conf=0.72)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“suggesting that successful implantation and mucosal trans-location of the transplanted bacteria, known to induce an IgG response against commensal bacteria, may preferentially occur in Rs (18).”
§ Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients > Fecal microbiota transplant induces persistent perturbation of recipients’ gut microbiome
What the sources say
- Supportedcites [18] Zeng MY, Immunity 44, 647– 658 (2016). 26944199 PMC4794373 source
The clause the citation is offered for is the background fact that mucosal translocation of gut bacteria is what induces an IgG response against commensal bacteria; the 'preferentially occur in Rs' inference is the citing authors' own conclusion from their FMT data and is not attributed content. Our copy states exactly that mechanism: the Results section 'Homeostatic Induction of Systemic IgG to Gram-Negative Symbiotic Bacteria' concludes that a selective group of gram-negative symbiotic bacteria breach the intestinal epithelial barrier and disseminate systemically to induce IgG, backed by detection of bacterial 16S rRNA in spleens/MLNs and Enterobacteriaceae being the predominant translocated families, and the Introduction/Discussion describe translocation-driven systemic IgG to symbiotic (commensal) bacteria. The only slippage is contextual — Zeng et al. studied resident murine symbionts under homeostatic conditions, not donor/transplanted bacteria or FMT responders — but the mechanism attributed to this source is stated there. (LLM, conf=0.82)
hedgedstates a possible causen = 6- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“administration of certain gut commensals or fecal microbiota transplantation (FMT) promotes anti–PD-1 efficacy in melanoma-bearing mice (10–12).”
§ Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients > Abstract
What the sources say
- Partly supportedcites [10] Gopalakrishnan V, Science 359, 97– 103 (2018). 29097493 PMC5827966 sourceExperimental — accuracy not yet measured
The paper’s FMT experiments (Fig. 4G–I; page unavailable) report reduced tumor growth and improved response to anti-PD-L1 therapy in mice receiving stool from patients who responded to anti-PD-1, compared with stool from nonresponders. Our copy does not report administering individual gut commensals to mice or testing anti-PD-1 efficacy in those mice. (LLM, conf=0.90)
- Partly supportedcites [11] Matson V, Science 359, 104– 108 (2018). 29302014 PMC6707353 sourceExperimental — accuracy not yet measured
In the indexed copy (section labeled Abstract; no page given), fecal transfer from responding patients improved tumor control in melanoma-bearing mice, and anti–PD-L1 treatment was effective in mice colonized with responder microbiota. The mouse experiment tested anti–PD-L1, not anti–PD-1; the copy also does not show that administering individual commensal species improved checkpoint-treatment efficacy in those mice. (LLM, conf=0.88)
- Not checked yetcites [12] Routy B, Science 359, 91– 97 (2018). 29097494 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In mice, composition of the gut microbiome modulates therapeutic activity of anti–PD-1 and anti–programmed death-ligand 1 (PD-L1)”
§ Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients > Abstract
What the sources say
- Supportedcites [10] Gopalakrishnan V, Science 359, 97– 103 (2018). 29097493 PMC5827966 source
The mouse FMT experiments (Results, Fig. 4G–I passage) state that germ-free mice transplanted with stool from anti–PD-1 responders had significantly reduced tumor growth (p=0.04) versus NR-FMT recipients, and that 'mice transplanted with R-FMT also exhibited improved responses to anti-PD-L1 therapy (Fig. 4I) in contrast to mice that were transplanted with stool from NR (NR-FMT)' — i.e. microbiome composition modulated therapeutic activity of both agents in mice. The abstract likewise reports enhanced anti-tumor immunity 'in germ-free mice receiving fecal transplants from responding patients,' and the closing discussion generalizes to modulation of anti–PD-1 response. The claim's mouse-only scope matches what the paper demonstrates causally in mice. (LLM, conf=0.87)
- Partly supportedcites [11] Matson V, Science 359, 104– 108 (2018). 29302014 PMC6707353 sourceExperimental — accuracy not yet measured
Our copy supports the anti–PD-L1 half of the claim with the paper's own in vivo data: in germ-free mice reconstituted with fecal material from responder versus nonresponder patients, 'Anti–PD-L1 was markedly efficacious in mice colonized with R microbiota yet completely ineffective in NR-derived mice (Fig. 3F)' (Results, Abstract section), and the Abstract states reconstitution with responder feces gave 'greater efficacy of anti-PD-L1 therapy'. However, this study did not administer anti–PD-1 to mice — its patient-level anti–PD-1 association is clinical (42 metastatic melanoma patients), and the mouse evidence for microbiome modulation of anti–PD-1 is explicitly credited to other work: 'Two additional studies have identified an association of the commensal microbiome with anti–PD-1 mAb efficacy in different solid cancers (7,14)... fecal transfer from R versus NR patients to GF mice was also able to recapitulate the patient phenotype' (Discussion). The intro likewise frames the mouse microbiome/anti–PD-L1 precedent as preclinical studies of reference (4). The attribution of the anti–PD-1-in-mice component to this source is therefore not supported by it. (LLM, conf=0.80)
- Not checked yetcites [12] Routy B, Science 359, 91– 97 (2018). 29097494 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
None of the sources cited for this claim have been checked yet.
In the paper
“Multiple circulating cytokines and chemokines decreased after FMT in Rs, including CCL2 (MCP1), CXCL8 (IL-8), and IL-18 that have been associated with negative outcomes to anti–PD-1 (32, 33), and IL-12p70 and IFN-γ (Fig. 4A, heatmap).”
§ Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients > Fecal microbiota transplant alters serum metabolome and cytokines in responders
What the sources say
- Could not verifycites [32] Gok Yavuz B, Sci. Rep 9, 3172 (2019). 30816272 PMC6395633 sourceExperimental — accuracy not yet measured
Our copy of Yavuz et al. (2019) is an in vitro study of cancer-associated fibroblasts educating CD14+ monocytes/macrophages from healthy donors; it contains no FMT cohort, no patient serum cytokine measurements, and no statement about CCL2/MCP-1, CXCL8/IL-8 or IL-18 levels changing after treatment or being associated with anti-PD-1 outcomes. The closest passages are the Results section 'Recruitment of monocytes by CAFs might be mediated by MCP-1 as well as SDF-1 cytokines' (blocking MCP-1 reduced monocyte migration in vitro) and the Discussion on PD-1+ TAMs citing Gordon et al. and Topalian et al., neither of which addresses circulating cytokine change or immunotherapy outcome association. Searched: 'CCL2 MCP-1 CXCL8 IL-18 negative outcomes anti-PD-1' and 'fecal microbiota transplantation responders serum cytokines' — no supporting passage. (LLM, conf=0.75)
- Not checked yetcites [33] Terme M, Cancer Res. 71, 5393– 5399 (2011). 21724589 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
28 more claims
Create a free account to see all 56 claims and to verify the 17 references still open.
- Probably not a substantial claim. 5
- It may state two separate claims as one. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, in several cohorts of patients with melanoma, the clinical response to anti-PD-1 antibodies correlated with the expression of the CUTC gene170 in the faecal microbiome40,91,128.”
From Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy (2023) · cites this paper as [128]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In two proof-of-concept trials with a total of 26 patients, responder-derived fecal microbiota transplantation (FMT) overcame PD-1 resistance in a third of patients with melanoma, suggesting that microbiome modulation could improve responsiveness to anti-PD-1 ICB10,11.”
From Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1 (2022) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This concurs with another clinical trial with a similar FMT-ICB design in which Akk was also associated with response to ICB post-FMT (Davar et al., 2021).”
From Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment (2021) · cites this paper as Davar et al., 2021
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similarly, Davar et al. (2021) found that combining FMT with anti-PD-1 therapy in refractory melanoma patients led to meaningful changes in gut microbial composition, increased activation of CD8+ natural killer-like T cells, recirculation of mucosa-associated invariant T cells, and distinct metabolic shifts associated with enhanced antitumor responses.”
From Microbiota-centered interventions to boost immune checkpoint blockade therapies (2025) · cites this paper as Davar et al., 2021
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The results of two phase 1 clinical studies NCT03341143 and NCT03353402 showed responder-derived FMT effectively relieved the resistance to α-PD-1/PD-L1 in some melanoma patients, having implications for modulating gut microbiota in cancer immunotherapy [26, 317].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [26]
Experimental — accuracy not yet measured
33 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Trimmomatic: a flexible trimmer for Illumina sequence data
Bolger, A. M., Lohse, M., & Usadel, B. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu170 · Cited by 65,548
Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400
Cytoscape: A software Environment for integrated models of biomolecular interaction networks
Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., Amin, N., Schwikowski, B., & Ideker, T. (2003) · Genome Research · doi:10.1101/gr.1239303 · Cited by 51,888
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Prokka: rapid prokaryotic genome annotation
Seemann, T. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu153 · Cited by 18,818
Metagenomic biomarker discovery and explanation
Segata, N., Izard, J., Waldron, L., Gevers, D., Miropolsky, L., Garrett, W. S., & Huttenhower, C. (2011) · Genome Biology · doi:10.1186/gb-2011-12-6-r60 · Cited by 16,192
Comprehensive Integration of Single-Cell Data
Stuart, T., Butler, A., Hoffman, P., Hafemeister, C., Papalexi, E., Mauck, W. M., Hao, Y., Stoeckius, M., Smibert, P., & Satija, R. (2019) · Cell · doi:10.1016/j.cell.2019.05.031 · Cited by 15,453
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Complex heatmaps reveal patterns and correlations in multidimensional genomic data
Gu, Z., Eils, R., & Schlesner, M. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw313 · Cited by 10,034
Cited by
Items 901–1,000 of 1,002
Harnessing Microbiota to Improve Immunotherapy for Gastrointestinal Cancers
Goc, J., & Sonnenberg, G. F. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0164 · Cited by 8
Intestinal Microbiota: The Driving Force behind Advances in Cancer Immunotherapy
Dai, Z., Fu, J., Peng, X., Tang, D., & Song, J. (2022) · Cancers · doi:10.3390/cancers14194796 · Cited by 9
Targeting Innate Immunity in Glioma Therapy
Gillard, A. G., Shin, D. H., Hampton, L. A., Lopez-Rivas, A. R., Parthasarathy, A., Fueyo-Margareto, J., & Gomez‐Manzano, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25020947 · Cited by 11
The role of the gut microbiome in regulating the response to immune checkpoint inhibitor therapy
Dean, N. J., d’Arienzo, P. D., Ibraheim, H., Lee, K. A., Olsson-Brown, A. C., Pinato, D. J., & Powell, N. (2024) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2024.101944 · Cited by 9
Fungal influence on immune cells and inflammatory responses in the tumor microenvironment (Review)
Zhang, J., Feng, Y., Li, D., & Shi, D. (2024) · Oncology Letters · doi:10.3892/ol.2024.14796 · Cited by 10
Skin microbiome engineering: Challenges and opportunities in skin diseases treatment
Lyu, Y., Shen, J., Che, Y., & Dai, L. (2025) · iMetaOmics. · doi:10.1002/imo2.70012 · Cited by 10
“Some studies have applied gut microbiome ‐ based treatments for melanoma, such as engineered probiotics and fecal microbiota transplantation [112, 113].”
Unraveling the Role of the Microbiota in Cancer Immunotherapy: A New Frontier
Wang, S., Li, S., Zhang, M., Liu, R., Ye, X., Mao, S., Yu, J., Xie, X., & Tan, W. (2025) · Research · doi:10.34133/research.0744 · Cited by 13
Tajima, K., Hosonuma, M., Funayama, E., Isobe, J., Baba, Y., Murayama, M., Narikawa, Y., Toyoda, H., Tsurui, T., Maruyama, Y., et al. (2025) · International Journal of Cancer · doi:10.1002/ijc.35472 · Cited by 13
“Additionally, ICI responses can be improved through fecal transplants from responders 7 or healthy individuals, 8 highlighting the importance of gut microbiota.”
The Interplay of Cross‐Organ Immune Regulation in Inflammation and Cancer
Dou, J., Jiang, J., Xue, Y., Jiang, X., Jiang, Y., Xiao, P., & Xu, J. (2025) · MedComm · doi:10.1002/mco2.70249 · Cited by 10
“In addition, fecal microbiota transplantation (FMT) and anti-PD-1 therapy were able to overcome anti-PD-1 resistance in the PD-1 advanced melanoma subgroup by altering the structure of the gut microbiome and reprogramming the tumor microenvironment [59].”
Roznovan, C. N., Marutescu, L. G., & Pîrcălăbioru, G. G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136177 · Cited by 13
Han, W., Zhou, Y., Wang, Y., Liu, X., Sun, T., & Xu, J. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1591076 · Cited by 12
Bryson, S., Sisson, Z., Nelson, B., Grove, J., Reister, E., Liachko, I., Auch, B., Graiziger, C. T., & Khoruts, A. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2559019 · Cited by 9
Jia, R. F., Xiao, C., Zhang, Y., Hu, L.-Y., Jun-jun, Y., Zuo, R., Hu, Y., Xie, Y.-H., Ma, X., Li, Q., et al. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101311 · Cited by 11
Makkar, S. K., & Bishnupuri, K. S. (2025) · Frontiers in Physiology · doi:10.3389/fphys.2025.1676796 · Cited by 11
Lu, L., Johnson, C. H., Khan, S. A., & Irwin, M. (2026) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2026.01.004 · Cited by 11
Tumor Immunotherapy and Microbiome: From Bench‐to‐Bedside Applications
Lin, A., Xiong, M., Jiang, A., Chen, L., Huang, L., Li, K., Wong, H. Z. H., Zhang, J., Liu, Z., Cheng, Q., et al. (2026) · MedComm · doi:10.1002/mco2.70454 · Cited by 11
The tumor ecosystem: Rewiring an open, systemically integrated network for therapeutic gain
Chiodelli, P., Papait, A., Agoni, L., Quaglia, F., Silini, A. R., & Parolini, O. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119047 · Cited by 12
Hu, S., Luo, C., Wan, S., Zhang, S., Li, N., Liu, G., & Zhao, L.-Y. (2026) · BMC Cancer · doi:10.1186/s12885-026-15655-6 · Cited by 10
Self-citationEngineering microbial metabolites to modulate tumor immunity and advance cancer immunotherapy
Chigozie, V. U., & Esimone, C. O. (2026) · Discover Immunity. · doi:10.1007/s44368-026-00019-w · Cited by 11
“Longitudinal follow-up from melanoma FMT trials reported no treatment-related deaths and showed that donor strains gradually declined over 6–12 months, stabilizing at partial engraftment levels [6, 24].”
InfluentialA comprehensive review of mechanisms underlying resistance to immune checkpoint inhibitors
Bertucci, A., -, T. K., Billon, E., Fernez, T., & Rochigneux, P. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1735741 · Cited by 12
Microbe-driven immune suppression in colorectal cancer: the Fusobacterium nucleatum playbook
Wuyi, W., & Tao, P. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1795703 · Cited by 14
“…that microbiome manipulation can partially overcome primary resistance: fecal microbiota transplantation (FMT) from responders, combined with anti – PD-1 therapy, induced objective responses in a subset of patients and promoted favorable immune remodeling within the tumor microenvironment (88, 89).”
Gonçalves, M., Lopes, C. C. C., & Silva, P. (2024) · Tissue and Cell · doi:10.1016/j.tice.2024.102306 · Cited by 13
Facts and Hopes in Using Omics to Advance Combined Immunotherapy Strategies
Augustin, R. C., Cai, W. L., Luke, J. J., & Bao, R. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2241 · Cited by 7
Melanoma—Modern Treatment for Metastatic Melanoma
Dimitrova, M., & Weber, J. S. (2024) · The Cancer Journal · doi:10.1097/ppo.0000000000000707 · Cited by 11
Nakamoto, S., Kajiwara, Y., Taniguchi, K., Hida, A. I., Miyoshi, Y., Kin, T., Yamamoto, M., Takabatake, D., Kubo, S., Hikino, H., et al. (2024) · Breast Cancer Research and Treatment · doi:10.1007/s10549-024-07395-7 · Cited by 13
“One study demonstrated that fecal microbiota transplantation modulated immune responses, such as peripheral and intratumoral CD8+ T cell activation [28].”
Immunotherapy efficacy and toxicity: Reviewing the evidence behind patient implementable strategies
Verhaert, M., & Aspeslagh, S. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114235 · Cited by 11
PD‐1 blockade treatment in melanoma: Mechanism of response and tumor‐intrinsic resistance
Wang, T., Ma, W., Zou, Z., Zhong, J., Lin, X., Liu, W., Sun, W., Hu, T., Xu, Y., & Chen, Y. (2024) · Cancer Science · doi:10.1111/cas.16398 · Cited by 10
The influence of microbiota on the efficacy and toxicity of immunotherapy in cancer treatment
Mahmoudian, F., Gheshlagh, S. R., Hemati, M., Farhadi, S., & Eslami, M. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-10188-2 · Cited by 15
“Numerous studies have demonstrated the involvement that specific gut microbiota, including Enterococcus , Akker-mansia [64], Bifidobacterium , Ruminococcaceae [14], and in conjunction with pembrolizumab [59, 60].”
Epigenetic mechanisms in melanoma development and progression
Joo, H., Olea, X. D., Zhuang, A., Zheng, B., Kim, H., & Ronai, Z. A. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.04.007 · Cited by 9
Feng, Z., & Vuky, J. (2021) · ONCOLOGY · doi:10.46883/onc.2021.3507.0410 · Cited by 8
Kim, S., Shin, J., Park, J., Cha, B., Seo, Y., Park, S.-H., Lee, J. H., Kim, J., & Kwon, G. (2022) · Medicine · doi:10.1097/md.0000000000029135 · Cited by 8
“[7] We report a case of CCS with a nephrotic syndrome that was refractory to steroid treatment and could not be treated with anti- TNF-a due to suspected active tuberculosis infection and improved by FMT.”
BackgroundHolistic immunomodulation for small cell lung cancer
Leung, E. L., Fan, X., Huang, J., Huang, C., Lin, H., & Cao, Y. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.11.012 · Cited by 8
Fecal Microbiota Transplantation Research over the Past Decade: Current Status and Trends
Hao, S., Yang, S., Zhang, N., & Cheng, H.-J. (2023) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2023/6981721 · Cited by 8
“In 2021, two trials published in Science showed that FMT from ICI responders can overcome the resistance to immunotherapy [11, 96].”
Targeting microbiome, drug metabolism, and drug delivery in oncology
Sumiyoshi, A., Fujii, H., & Okuma, Y. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114902 · Cited by 9
Tintelnot, J., Stein, A., Al‐Batran, S., Ettrich, T. J., Götze, T. O., Grün, B., Haag, G. M., Heuer, V., Hofheinz, R., Homann, N., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1272175 · Cited by 9
Cao, Y., Zhang, L., Xiong, F., Guo, X., Kan, X., Song, S., Liang, B., Liang, B., Li, Y., & Zheng, C. (2023) · Future Microbiology · doi:10.2217/fmb-2022-0234 · Cited by 9
Angrish, M. D., & Pezo, R. C. (2021) · Advances in Cancer Biology - Metastasis · doi:10.1016/j.adcanc.2021.100020 · Cited by 8
Antibiotic Therapy: The Cornerstone of Iatrogenic Resistance to Immune Checkpoint Inhibitors
Pinato, D. J., & Cortellini, A. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00049 · Cited by 8
Interaction of microbiota, mucosal malignancies, and immunotherapy—Mechanistic insights
Mager, L. F., Krause, T., & McCoy, K. D. (2024) · Mucosal Immunology · doi:10.1016/j.mucimm.2024.03.007 · Cited by 8
Microbiome‐driven anticancer therapy: A step forward from natural products
Guan, Y., Wu, D., Wang, H., & Liu, N. (2024) · mLife · doi:10.1002/mlf2.12118 · Cited by 8
Self-citationWong, M. K., Boukhaled, G. M., Armstrong, E., Liu, R., Heirali, A., Yee, N., Tsang, J., Spiliopoulou, P., Schneeberger, P. H. H., Wang, B. X., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010681 · Cited by 8
Shibano, M., Takahashi, M., Nakatsukasa, H., Ishigami, Y., Toyokawa, T., Taira, K., Kawaguchi, T., Nakamura, Y., & Kaneda, H. (2025) · Immunotherapy · doi:10.1080/1750743x.2025.2491300 · Cited by 7
Facts and Hopes: Toward the Next Quantum Leap in Melanoma
Flaherty, K. T., Aplin, A. E., Davies, M. A., Hacohen, N., Herlyn, M., Hoon, D. S. �., Hwu, P., Lotem, M., Mulé, J. J., Wargo, J. A., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-0278 · Cited by 9
Gut microbiota as a predictive tool for outcomes in IgA nephropathy
Dong, Y., Yan, G., Zhang, Y., Zhou, Y., & Shang, J. (2025) · Renal Failure · doi:10.1080/0886022x.2025.2514184 · Cited by 7
Xie, J., Zhao, S., Wu, D., Ma, C., Yan, W., Zhang, P., Lu, Q., Wan, Z., Tang, Q., Li, L., et al. (2025) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2025.08.044 · Cited by 7
Emerging strategies in colorectal cancer immunotherapy: enhancing efficacy and survival
Zhang, Y., Guan, H., Feng, X., Liu, M., Shao, J., Liu, M., He, J., Jin, Y., Zhu, J., & Zheng, C. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1616414 · Cited by 13
“Even more exciting is that fecal microbiota transplantation (FMT) has shown promise in enhancing immunotherapy ef fi cacy and overcoming resistance to ICIs in melanoma patients (132, 133).”
Harnessing Next‐Generation 3D Cancer Models to Elucidate Tumor‐Microbiome Crosstalk
Buzhor, M. G., Longobardi, G., Kandli, O., Krinsky, A., Avramoff, O., Katyal, A., Salomon, K., Miari, A., Venkert, D., Barnatan, T. T., et al. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202503198 · Cited by 12
The Microbiome and Genitourinary Cancers: A New Frontier
Winslow, T. B., Gupta, S., Vaddaraju, V., Guercio, B. J., & Sahasrabudhe, D. M. (2025) · Cancers · doi:10.3390/cancers17223606 · Cited by 7
Lucia, S. S. D., Nista, E. C., Candelli, M., Archilei, S., Deutschbein, F., Capuano, E., Gasbarrini, A., Franceschi, F., & Pignataro, G. (2025) · Cancers · doi:10.3390/cancers17223618 · Cited by 7
“In one clinical trial, three of fifteen anti-PD-1-refractory melanoma patients responded to FMT combined with pembrolizumab [119].”
Li, Q., & Liu, Y. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1701101 · Cited by 7
Microbiota and cancer immunotherapy: Mechanisms, clinical implications, and precision therapeutics
Wei, D., Sun, Y., Han, J., & Liu, J. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.12.002 · Cited by 9
Yoshinami, Y., Yamaguchi, S., Shoji, H., Okita, N. T., Takamaru, H., Hirose, T., Hirano, H., Takashima, A., Imazeki, H., Yamamoto, S., et al. (2025) · Future Oncology · doi:10.1080/14796694.2025.2599371 · Cited by 8
Yang, J., Dai, Y., & Li, J. (2026) · Oncology Reviews · doi:10.3389/or.2025.1687901 · Cited by 9
Stochasticity in cancer immunotherapy stems from rare but functionally critical Spark T cells
Salazar-Cavazos, E., Jia, D., Missolo-Koussou, Y., Kenet, A. L., Achar, S. R., Dada, H., Kondo, T., Krishnan, A. Y., Taylor, N. N., Klemen, N. D., et al. (2026) · Cell · doi:10.1016/j.cell.2025.12.026 · Cited by 8
Zhou, H., Sun, R., Nie, X., Xia, L., Dong, H., Liu, Y., Hou, S., Dong, W., Zhu, X., Yao, Y., et al. (2026) · Nature Microbiology · doi:10.1038/s41564-026-02279-6 · Cited by 14
“Pilot clinical trials showed that FMT from patients who are responsive to anti-PD-1 may overcome resistance to PD-1 blockade therapy 16,17 .”
Microbiota-derived metabolites as modulators of cancer immunotherapy response
Toner-Bartelds, C., Mimpen, I. L., Parra-Martinez, M., Burgering, B. M. T., & Voest, E. E. (2026) · Nature Communications · doi:10.1038/s41467-026-72178-1 · Cited by 10
“FMT has shown promise in improving ICB responses in clinical trials 10 – 12 .”
Understanding the human gut microbiome: from composition to disease association
Alali, M. A., & Shori, A. B. (2026) · Frontiers in Microbiomes · doi:10.3389/frmbi.2026.1717288 · Cited by 14
“…have shown that fecal microbiota transplantation (FMT) from immunotherapy responders into patients with refractory melanoma restored responsiveness to anti-PD-1 therapy, which was accompanied by immune reprogramming within the tumor micro-environment (Baruch et al., 2021; Davar et al., 2021).”
Arc1 and the microbiota together modulate growth and metabolic traits in Drosophila
Keith, S. A., Bishop, C. M., Fallacaro, S., & McCartney, B. M. (2021) · Development · doi:10.1242/dev.195222 · Cited by 14
The Urogenital System’s Role in Diseases: A Synopsis
Zerdan, M. B., Moukarzel, R., Naji, N. S., Bilen, Y., & Nagarajan, A. (2022) · Cancers · doi:10.3390/cancers14143328 · Cited by 8
“also showed the modulatory effect of FMT in melanoma patients on pembrolizumab [84].”
BackgroundMethodThe complex immunological role of Helicobacter in modulating cancer
Hand, T. W., & Overacre-Delgoffe, A. E. (2022) · Trends in Immunology · doi:10.1016/j.it.2022.08.002 · Cited by 10
Crosstalk between Gut Microbiota and Hepatocellular Carcinoma
Xie, C., & Pocha, C. (2023) · Gastrointestinal Disorders · doi:10.3390/gidisord5020013 · Cited by 7
Sah, V. R., Jespersen, H., Karlsson, J. W., Nilsson, L. M., Bergqvist, M., Johansson, I., Carneiro, A., Helgadóttir, H., Levin, M., Ullenhag, G. J., et al. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0490 · Cited by 7
“Today, a multitude of trials are combining ICIs with chemotherapy (10), radiotherapy (11), vaccines (12), targeted therapies (13), cellular therapies (14), and more (15).”
Potential role of gut microbes in the efficacy and toxicity of immune checkpoints inhibitors
Ma, J., Wei, Q., Cheng, X. M., Zhang, J., Zhang, Z., & Su, J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1170591 · Cited by 9
“The ineffectiveness of FMTmay be due to several factors, such as a decrease in the patient’s immunity, the absence of taxa needed for therapy effectiveness in the FMT, and the disruption of the host microorganism due to graft failure (Davar et al., 2021).”
BackgroundThe effect of diet and nutrition on T cell function in cancer
Zhou, X., Wang, Z., & Yuan, K. (2023) · International Journal of Cancer · doi:10.1002/ijc.34668 · Cited by 10
“The gut microbiota has been demonstrated to modulate immune response in melanoma patients.(150) Recently, scientists have found that Lactobacillus reuteri, a super-common probiotic, is promising as an “assistant” for cancer immunotherapy.”
The Value of Microbes in Cancer Neoantigen Immunotherapy
Tian, J., & Ma, J. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082138 · Cited by 8
“In this trial, six of fifteen patients demonstrated a beneficial response, with three patients achieving remission and three patients having stable disease [156].”
BackgroundStover, M. A., Tinoco-Bravo, B., Shults, C. A., Marouk, S., Deole, R., & Manjarrez, J. R. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1207705 · Cited by 10
“The influence of the microbiome on health span is a growing area of interest, with the recent chemotherapeutic advances with fecal transplants efficiently conferring sensitivity to known treatments (Davar et al., 2021).”
Cancer energy reprogramming and the immune responses
Yuan, X., Ouédraogo, S. Y., Trawally, M., Tan, Y., & Bajinka, O. (2024) · Cytokine · doi:10.1016/j.cyto.2024.156561 · Cited by 9
Microbes and vitamin D aid immunotherapy
Franco, F., & McCoy, K. D. (2024) · Science · doi:10.1126/science.adp1309 · Cited by 7
Oliva, M., Heirali, A., Watson, G. A., Rooney, A. M., Cochrane, K., Jennings, S., Taylor, R., Xu, M., Hosni, A., Hope, A. J., et al. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02701-y · Cited by 8
“…(FMT) via colonoscopy, using stools from ICI responders has shown encouraging results, but the logistical dif fi culties of this approach and the risk of toxicity, including fatal bloodstream infections from donor-derived anti-biotic-resistant organisms, have limited its development [3 – 5].”
Hazra, R., Chattopadhyay, S., Mallick, A., Gayen, S., & Roy, S. (2024) · Medical Oncology · doi:10.1007/s12032-024-02416-3 · Cited by 8
“The combination of FMT and immunotherapy are safe and, importantly, it helped reverse resistance to immunotherapy in some melanoma patients [61, 62].”
Could intratumoural microbiota be key to unlocking treatment responses in hepatocellular carcinoma?
Yu, K. L., & Shen, S. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.115195 · Cited by 8
Single-cell nanocapsules of gut microbiota facilitate fecal microbiota transplantation
Hou, W., Cao, Y., Wang, J., Yin, F., Wang, J., Guo, N., Wang, Z., Lv, X., Ma, C., Chen, Q., et al. (2025) · Theranostics · doi:10.7150/thno.104852 · Cited by 8
Progress in the Study of Intratumoral Microorganisms in Hepatocellular Carcinoma
Song, Y., Tian, S., Li, Z., Miao, J., Wu, M., Xu, T., Wu, X., Qiao, J., Zhang, X., Zhao, H., et al. (2025) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s496964 · Cited by 7
Rafie, E., Zugman, M., Pal, S. K., Routy, B., & Elkrief, A. (2024) · European Urology Focus · doi:10.1016/j.euf.2024.12.009 · Cited by 7
Huang, W., Jiang, T., He, J., Ruan, J., Wu, B., Tao, R., Xu, P., Wang, Y., Chen, R., Wang, H., et al. (2025) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-025-10471-z · Cited by 9
“…m e n t o f t h e t hy r o i d g l a nd a nd i s o f t e n a ss o c i a t e d w it h i od i n e d e fi c i e n c y [ 276 ] fecal flora from individuals responsive to PD-1 inhibitors were transplanted into patients with drug-resistant malignant melanoma, indicating potential for TC treatment [180].”
Self-citationLi, Z., & Liu, H. (2025) · Food Chemistry · doi:10.1016/j.foodchem.2025.144852 · Cited by 10
Fecal microbiota transplantation: can it circumvent resistance to PD-1 blockade in melanoma?
Derosa, L., & Zitvogel, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00585-5 · Cited by 6
“and Davar et al.(2) bring up the first proof-of-concept that fecal microbiota transplantation (FMT) transfer clinical benefit in metastatic melanoma patients primarily resistant to immune checkpoint blockade (ICB).”
BackgroundMethodInfluentialMicrobiota and Hematological Diseases
D’Angelo, G. (2022) · International Journal of Hematology-Oncology and Stem Cell Research · doi:10.18502/ijhoscr.v16i3.10139 · Cited by 11
Hilakivi-Clarke, L. A., Verma, V., McDermott, M., Koak, P., & Andrade, F. D. O. (2022) · Frontiers in Microbiomes · doi:10.3389/frmbi.2022.1049688 · Cited by 7
“The two key observations are: (i) ICBrefractory cancer patients can become responsive after receiving FMT from an ICB-responding donor (Davar et al., 2021; Baruch et al., 2021), and (ii) antibiotics that induce gut dysbiosis and eliminate critical commensal bacteria impair the effectiveness of ICBs (Huang et al.”
BackgroundMethodInfluentialTumor resident microbiota and response to therapies: An insight on tissue bacterial microbiota
Pirini, F., Cortesi, M., Tumedei, M. M., Zanoni, M., Ravaioli, S., & Bravaccini, S. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1048360 · Cited by 7
“donors or responders to therapy has shown good success in immune checkpoint blockade (ICB)-resistant patients, increasing tumor immune infiltrate and increasing therapy-associated metabolites in serum (Baruch et al., 2021; Davar et al., 2021).”
BackgroundBhatt, A., Haslam, A., & Prasad, V. K. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04656-8 · Cited by 8
Linking the microbiome to CAR-T cell responses
DeFilipp, Z. M., & Maus, M. V. (2023) · Nature Medicine · doi:10.1038/s41591-023-02272-0 · Cited by 8
Gastrointestinal injury induced by immunomodulators: A review article
Zhang, P., Mao, R., Zhang, C., Qiu, Y., & Chen, M. (2023) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848231158549 · Cited by 10
Fecal transplantation in patient with metastatic melanoma refractory to immunotherapy: A case report
del Giglio, A., & Atuí, F. C. (2023) · World Journal of Clinical Cases · doi:10.12998/wjcc.v11.i24.5830 · Cited by 7
Factors of faecal microbiota transplantation applied to cancer management
Liu, Y.-H., Chen, J., Chen, X., & Liu, H. (2024) · Journal of drug targeting · doi:10.1080/1061186x.2023.2299724 · Cited by 6
“FMt and anti-PD-1 therapy alter the gut microbiota and reprogram the tumour micro-environment to overcome patient resistance to anti-PD-1 therapy [65].”
BackgroundMicrobial metabolite as icebreaker for immunotherapy
Tang, Y., & Kang, Y. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.03.003 · Cited by 7
Clinical Applications of the Gut Microbiome in Genitourinary Cancers
Nguyen, C. B., & Vaishampayan, U. N. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_100041 · Cited by 8
Faecal transplants can treat some cancers — but probably won’t ever be widely used
Drew, L. (2024) · Nature · doi:10.1038/d41586-024-02212-z · Cited by 6
Effects of antibiotics on immunotherapy in patients with metastatic nonsmall cell lung cancer
Hu, T., Li, L., Cui, J., Song, X., Zhu, H., Hou, Z. W., & Yuan, S. (2024) · European Journal of Cancer Prevention · doi:10.1097/cej.0000000000000912 · Cited by 7
“It has been found that the intestinal flora can regulate tumor immunity and affect the therapeutic effect by affecting the efficacy of ICIs (Baruch et al. , 2021; Davar et al. , 2021; Kawanabe-Matsuda et al. , 2022).”
Luan, B., Yang, Y., Yang, Q., Li, Z., Xu, Z., Chen, Y., Wang, M., Chen, W., & Ge, F. (2025) · AMB Express · doi:10.1186/s13568-025-01866-w · Cited by 7
“Additionally, fecal microbiota transplantation (FMT) and anti-PD-1 therapy have been shown to remodel the gut microbiome, subsequently reshaping the tumor microenvironment and effectively overcoming resistance to anti-PD-1 therapy in subsets of advanced melanoma patients (Davar et al. 2021).”
Hadjigeorgiou, A. G., Harkos, C., Mishra, A. K., Morad, G., Johnson, S. B., Ajami, N. J., Wargo, J. A., Munn, L. L., Stylianopoulos, T., & Jain, R. K. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-2232 · Cited by 17
Adjuvant Immunotherapy in Stage IIB/IIC Melanoma: Current Evidence and Future Directions
Prkačin, I., Brkić, A., Pondeljak, N., Mokos, M., Gaćina, K., & Šitum, M. (2025) · Biomedicines · doi:10.3390/biomedicines13081894 · Cited by 10
“Studies indicate that melanoma patients who respond to anti-PD-1 therapy have a distinct gut microbiome composition compared to those who do not respond [48].”
Ma, C., Awosika, J. A., B., M. C. M., Coffman, K., Xie, C., Skorupan, N., Hrones, D. M., Liu, M., Ma, L., Wood, B. J., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217975 · Cited by 11
Self-citationWang, R., Zhong, D., Jin, K., Tong, A., Li, L., Zheng, Y., Cui, J., Liu, X., Wang, Z., & Zhou, M. (2025) · Cell Biomaterials · doi:10.1016/j.celbio.2025.100182 · Cited by 8
Microbiome unlocks cancer immunotherapeutic potential: State of the art and future
Luo, H.-Y., Cao, L., Zhou, K., Xiao, Y., Li, Z., Liu, B., & Bu, L. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.08.001 · Cited by 6
Microbial Metabolic Pathways Guide Response to Immune Checkpoint Blockade Therapy
Mimpen, I. L., Battaglia, T., Parra-Martinez, M., Toner-Bartelds, C., Zeverijn, L. J., Geurts, B. S., Verkerk, K., Hoes, L. R., van Renterghem, A. W. J., Noë, M., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-1669 · Cited by 11
Yuan, S., Bremmer, A., Yang, X., & Hu, Q. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.11.023 · Cited by 8
Unveiling the interplay between microbiota and PD1/PD-L1 axis in tumor immunity and immunotherapy
Lu, Q., Wu, J., Yu, X., Qian, J., & Song, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1690374 · Cited by 6
“…patients who did not respond initially, infusion of fecal microbiota from responders (e.g., in trial NCT03341143) could reshape the gut microbiota and reverse the immunosuppressive tumor microenvironment in a subset of patients (approximately 40%), thereby overcoming drug resistance (56).”
InfluentialAscari, S., Chen, R., Sinno, A. D., Stefanini, B., Cescon, M., Serenari, M., Mosconi, C., & Tovoli, F. (2026) · World Journal of Gastroenterology · doi:10.3748/wjg.v32.i3.111528 · Cited by 6
“Two phase 1 studies for patients with melanoma confirmed the feasibility and efficacy of FMT from donors who achieved tumor response with ICIs in patients with tumor progression under ICIs[56,57].”
Lou, S., Li, W., Wang, G., Qian, H., & Zhou, J. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105217 · Cited by 9
Metadata
- Authors
- Davar, D., Dzutsev, A. K., McCulloch, J. A., Rodrigues, R. R., Chauvin, J.-M., Morrison, R. M., Deblasio, R. N., Menna, C., Ding, Q., Pagliano, O., Zidi, B., Zhang, S., Badger, J. H., Vetizou, M., Cole, A. M., Fernandes, M. R., Prescott, S., Costa, R. G. F., Balaji, A. K., Morgun, A., Vujkovic-Cvijin, I., Wang, H., Borhani, A. A., Schwartz, M. B., Dubner, H. M., Ernst, S. J., Rose, A., Najjar, Y. G., Belkaid, Y., Kirkwood, J. M., Trinchieri, G., & Zarour, H. M.
- Affiliations
- University of Pittsburgh (US)
- National Cancer Institute (US)
- Frederick National Laboratory for Cancer Research (US)
- Department of Medicine and UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA 15213, USA.
- Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
- Oregon State University (US)
- National Institutes of Health (US)
- Corresponding author
- Davar, Diwakar
- Dzutsev, Amiran K.
- Trinchieri, Giorgio
- Zarour, Hassane M.
- ORCID
- Davar, Diwakar
- Dzutsev, Amiran K.
- McCulloch, John A.
- Rodrigues, Richard R.
- Chauvin, Joe-Marc
- Morrison, Robert M.
- Pagliano, Ornella
- Zidi, Bochra
- Zhang, Shuowen
- Badger, Jonathan H.
- Vetizou, Marie
- Cole, Alicia M.
- Fernandes, Miriam R.
- Prescott, Stephanie
- Costa, Raquel G. F.
- Balaji, Ascharya K.
- Morgun, Andrey
- Vujkovic-Cvijin, Ivan
- Wang, Hong
- Borhani, Amir A.
- Schwartz, Marc B.
- Dubner, Howard M.
- Najjar, Yana G.
- Belkaid, Yasmine
- Kirkwood, John M.
- Trinchieri, Giorgio
- Zarour, Hassane M.
- Venue
- Science
- Published
- 2021-02-05
- Volume
- 371
- Issue
- 6529
- Pages
- 595-602
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC8097968
- OpenAlex
- W3126208996
- Cited by
- 1,781
- References
- 54
- Citations by year
- 2026: 396 · 2025: 328 · 2024: 315 · 2023: 316 · 2022: 282 · 2021: 141
- FWCI
- 97.40
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (CA228181, CA222203)
- Melanoma Research Foundation (MRFBC 2020)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- fecal microbiota transplantation, anti-PD-1 therapy, melanoma, immunotherapy resistance, gut microbiota, CD8+ T cell activation, interleukin-8, myeloid cells, immunosuppression
- MeSH terms
- Gastrointestinal Microbiome, Fecal Microbiota Transplantation, Antineoplastic Agents, Immunological, Humans, Lymphocyte Activation, Melanoma, Skin Neoplasms, Interleukin-8, Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes, Drug Resistance, Neoplasm, Myeloid Cells, Tumor Microenvironment, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.